Your new experience awaits. Try the new design now and help us make it even better

ORIGINAL RESEARCH article

Front. Oncol.

Sec. Pharmacology of Anti-Cancer Drugs

Volume 15 - 2025 | doi: 10.3389/fonc.2025.1622666

Andrographolide Suppresses Chondrosarcoma Cell Migration and Invasion by Inhibiting the PI3K/Akt/mTOR Signaling Pathway and Activating Autophagy

Provisionally accepted
Chun-Fei  WuChun-Fei WuShuo  YangShuo YangXian-Xing  ZhongXian-Xing ZhongYong  LinYong LinShuai  FanShuai FanPeng  LiPeng LiZujian  LiangZujian Liang*
  • Guangzhou University of Chinese Medicine, Guangzhou, China

The final, formatted version of the article will be published soon.

Objective Chondrosarcoma, a malignant bone tumor, exhibits a high incidence rate. This study employed network pharmacology and cell-based experiments to explore the molecular mechanisms by which andrographolide(Andro) suppressed the migration and invasion of chondrosarcoma cells. Methods Andro's target genes were identified through integration of data from SuperPred, SEA, STITCH, Pharmmapper, HERB, HIT-2, and Swiss Target Prediction databases, and subsequently cross-referenced with chondrosarcoma-related genes. A protein–protein interaction(PPI) network was constructed using the STRING platform, followed by GO functional annotation and KEGG pathway enrichment analyses of potential targets with R software. Molecular docking assessed the binding affinities between Andro and key targets. Based on network pharmacology data, in vitro experiments validated Andro's impact on the migration and invasion of chondrosarcoma cells and investigated its underlying mechanisms. Results A total of 167 potential targets for Andro were identified. The PPI network highlighted PI3K, Akt, and mTOR as core targets. KEGG pathway analysis revealed that Andro's inhibitory effects on cell migration and invasion were linked to the PI3K/Akt, HIF-1, and T-cell receptor signaling pathways. Molecular docking confirmed that the binding energies for the Andro-PI3K, Andro-Akt, and Andro-mTOR complexes were <–5 kcal/mol. Wound healing and transwell assays demonstrated that Andro(5 and 20 μM) treatment significantly reduced the wound healing rate and impaired the migratory and invasive abilities of chondrosarcoma cells after 24 hours (p<0.05) compared to controls. Western blotting (WB) analysis showed that Andro (5, 20, and 50 μM) notably downregulated vimentin and MMP-9 expression while upregulating E-cadherin in chondrosarcoma cells (p<0.05 for all). Furthermore, Andro(5, 20, and 50 μM) decreased the p-mTOR/mTOR, p-PI3K/PI3K, and p-Akt/Akt ratios in SW1353 and Hs819.T cells. WB results also revealed that Andro (5, 20, and 50 μM) reduced p62 expression, while Beclin-1 expression and the LC3A/B-Ⅱ/LC3A/B-Ⅰratio increased in SW1353 and Hs819.T cells. Confocal microscopy demonstrated a significant increase in autophagic flux in Andro-treated SW1353 cells. Andro's effects were attenuated by autophagy inhibitor chloroquine, indicating its pharmacological action via autophagy inhibition in chondrosarcoma cells. Conclusion Therefore, Andro could reduce the migration and invasion of chondrosarcoma cells by modulating the PI3K/Akt/mTOR signaling pathway, alleviating autophagy inhibition, and subsequently promoting autophagic activity.

Keywords: andrographolide, Chondrosarcoma, PI3K/AKT/mTOR, Network Pharmacology, in vitro experiments

Received: 04 May 2025; Accepted: 12 Sep 2025.

Copyright: © 2025 Wu, Yang, Zhong, Lin, Fan, Li and Liang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence: Zujian Liang, Guangzhou University of Chinese Medicine, Guangzhou, China

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.